Skip to main content
Premium Trial:

Request an Annual Quote

W. Thomas Amick Named to Quaker Bioventures Board; David Ferrick New VP of Guava; Donald Steen New Ameripath CEO; and Others

NEW YORK, July 7 (GenomeWeb News) - W. Thomas Amick has been appointed to the advisory board of Quaker Bioventures , the Philadelphia-based venture capital firm said today. Quaker focuses on investments in life sciences companies in the US Mid-Atlantic region. Amick had a 30-year career as an executive with Johnson & Johnson. He was most recently vice president of J&J Development Corporation, and also was president of Jannsen-Ortho and Ortho Biotech Europe, as well as vice president of the company's oncology franchise.

 


 

David Ferrick has joined Guava Technologies of Hayward, Calif., as vice president of biology and clinical applications, the company said July 6. Ferrick previously was CEO and director of Sagres Discovery of Davis, Calif., a company he co-founded in 1999. Prior to joining Sagres, he was director of molecular and cellular biology at Rigel Pharmaceuticals in South San Francisco, Calif. He was also an associate professor of pathology, microbiology, and immunology at the University of California, Davis . Ferrick holds a PhD in immunology from Georgetown University .

 


 

Bernard Kasten has been named CEO of SIGA Technologies , the New York-based company said July 6. Previously Kasten was vice president of medical affairs of the MedPlus subsidiary of Quest Diagnostics . Kasten, a member of SIGA's board of directors since May 2003, is a graduate of the Ohio State University College of Medicine.

 


 

Pamela Kirby has been named to the board of directors of Oscient Pharmaceuticals, the company said July 1.

 

Kirby was most recently CEO of Quintiles Transnational Corporation, which develops product development and commercialization strategies for the pharmaceutical and biotechnology industries. She previously was director of global pharmaceutical strategic marketing and product life cycle management for F. Hoffman-La Roche, and commercial director at British Biotech, which is now Vernalis. She was also vice president of corporate strategy, marketing, and business development at Astra, now AstraZeneca.

 


 

Donald Steen has been appointed CEO of Ameripath, the cancer diagnostics company said July 1. Steen is currently chairman of the board of the Riviera Beach, Fl.-based company, and also chairman of United Surgical Partners, which he founded in February 1998. Steen additionally founded Medical Care International, a surgery center provider, in 1982.


 

Wenpei Su has been appointed director of genomics applications at CeMines of Evergreen, Colo., the company said July 1. Su previously was at Dow Chemical , and before that at Torrey Mesa Research Institute . He has also served as genomic group leader with Monsanto . Su holds a PhD in molecular biology and biochemistry from Cornell University .


 

Knud Aunstrup has joined Nuevolution of Copenhagen, Denmark, as CEO, replacing Zaed Subhan , who resigned for personal reasons, the company said July 1. Aunstrup previously led Novo Nordisk's biotechnology division with global responsibility for R&D. He was also president of Novo Nordisk China .


 

Max Link , a director of Protein Design Labs since 1993, has been elected chairman of the board, the company said June 30. Link was CEO of Boeringher Mannheim-Therapeutics between 1993 and 1994, and also CEO of Cornage, of which Boeringher Mannheim-Therapeutics was the pharmaceutical division. He also was the chairman of Sandoz between 1992 and 1993, after holding various positions at Sandoz starting in 1971.

 

Link succeeds Laurence Jay Korn, who had been chairman of the board of the Fremont, Calif., company since 1987.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.